OncoMatch

OncoMatch/Clinical Trials/NCT07006506

A Study of Belumosudil in People at Risk of Developing Graft-Versus-Host Disease After a Stem Cell Transplant

Is NCT07006506 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Belumosudil for graft versus host disease.

Phase 2RecruitingMemorial Sloan Kettering Cancer CenterNCT07006506Data as of May 2026

Treatment: Belumosudil — The purpose of this study is to find out whether adding belumosudil to a usual approach for reducing the risk of graft-versus-host disease (GVHD) may be an effective GVHD prevention approach for people with blood cancer who have a stem cell transplant. The investigators will also look at the safety of the study approach.

Check if I qualify

Extracted eligibility criteria

Cancer type

Acute Myeloid Leukemia

Acute Lymphoblastic Leukemia

Non-Hodgkin Lymphoma

Multiple Myeloma

Myelodysplastic Syndrome

Chronic Lymphocytic Leukemia

Prior therapy

Cannot have received: belumosudil

Lab requirements

Blood counts

engraftment: ANC ≥500/μL and platelets ≥ 20000/μL on 3 consecutive measurements (each occurring at least 1 day apart); no platelet transfusion within 7 days before the first measurement

Kidney function

glomerular filtration rate (GFR) ≥ 30 mL/min/1.73 m2

Liver function

ALT and AST ≤ 3x upper limit of normal (ULN); total bilirubin ≤1.5 x ULN (unless benign congenital hyperbilirubinemia)

Engraftment is defined as ANC≥500/μL and platelets ≥ 20000/μL on 3 consecutive measurements (each occurring at least 1 day apart). The patient must not have had a platelet transfusion within 7 days before the first measurement. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 3x upper limit of normal (ULN). Total bilirubin ≤1.5 x ULN (unless benign congenital hyperbilirubinemia). Glomerular filtration rate (GFR) ≥ 30 mL/min/1.73 m2

Structured fields extracted by AI. May contain errors — verify against the official protocol.

US trial sites

  • Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities) · Basking Ridge, New Jersey
  • Memorial Sloan Kettering Monmouth (Limited Protocol Activities) · Middletown, New Jersey
  • Memorial Sloan Kettering Bergen (Limited Protocol Activities) · Montvale, New Jersey
  • Memorial Sloan Kettering Suffolk-Commack (Limited protocol activity) · Commack, New York
  • Memorial Sloan Kettering Westchester (Limited Protocol Activities) · Harrison, New York

Showing up to 5 US sites. See all sites on ClinicalTrials.gov →

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify